• Protocols

• EAY191N4

  OPEN TO ACCRUAL

  Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
  
  

• NRGGY019

  OPEN TO ACCRUAL

  Ph III Trial of Pac/Carboplat/Letrozole vs Letrozole in Pts w/ II-IV Serous Ovary or Peritoneum Canc